SK Biopharmaceuticals: Epilepsy trials

The registry lists 12 Epilepsy studies with SK Biopharmaceuticals as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 2 5Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedNCT01397968Phase 2Results posted
• Cenobamate Expanded Access Program (EAP)Approved for marketingNCT04513860
• An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.CompletedNCT00991757Phase 3
• An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresCompletedNCT00744731Phase 3
• A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.CompletedNCT00740623Phase 3
• Efficacy of YKP3089 in Patients With Photosensitive EpilepsyCompletedNCT00616148Phase 2
• Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.TerminatedNCT00563459Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00433667Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00425282Phase 3
• Safety and Efficacy of 333369 in the Treatment of Partial EpilepsyCompletedNCT00228969Phase 2
• An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyCompletedNCT00210652Phase 2
• An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyCompletedNCT00210522Phase 2